Patents by Inventor Raghida BUKHALID

Raghida BUKHALID has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS, COMBINATIONS AND METHODS OF USE
    Publication number: 20230398229
    Abstract: The present disclosure provides combinations comprising HER2-targeted STING agonist antibody-drug conjugates and HER2-targeted therapies or immunotherapies. The present disclosure also provides uses of the combinations in treatment, e.g., treatment of cancer.
    Type: Application
    Filed: March 7, 2023
    Publication date: December 14, 2023
    Inventors: Raghida A. BUKHALID, Naniye Cetinbas, Marc I. Damelin, Timothy B. Lowinger, Dorin Toader
  • ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS
    Publication number: 20230321048
    Abstract: The present disclosure provides scaffolds and antibody-drug conjugates (ADCs) comprising a stimulator of interferon genes (STING). The present disclosure also provides uses of the ADCs in treatment, e.g., treatment of cancer.
    Type: Application
    Filed: December 19, 2022
    Publication date: October 12, 2023
    Inventors: Jeremy R. DUVALL, Keith W. BENTLEY, Raghida A. BUKHALID, Naniye CETINBAS, Marc I. DAMELIN, Eugene W. KELLEHER, Timothy B. LOWINGER, Joshua D. THOMAS, Dorin TOADER, Ling XU, Liping YANG
  • ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS
    Publication number: 20230172910
    Abstract: The present disclosure provides scaffolds and antibody-drug conjugates (ADCs) comprising a stimulator of interferon genes (STING). The present disclosure also provides uses of the ADCs in treatment, e.g., treatment of cancer.
    Type: Application
    Filed: December 20, 2022
    Publication date: June 8, 2023
    Inventors: Jeremy R. DUVALL, Keith W. BENTLEY, Raghida A. BUKHALID, Naniye CETINBAS, Marc I. DAMELIN, Eugene W. KELLEHER, Timothy B. LOWINGER, Joshua D. THOMAS, Dorin TOADER, Ling XU, Liping YANG
  • ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS
    Publication number: 20220378749
    Abstract: The present disclosure provides scaffolds and antibody-drug conjugates (ADCs) comprising a stimulator of interferon genes (STING). The present disclosure also provides uses of the ADCs in treatment, e.g., treatment of cancer.
    Type: Application
    Filed: April 2, 2021
    Publication date: December 1, 2022
    Inventors: Jeremy R. DUVALL, Keith W. BENTLEY, Raghida A. BUKHALID, Naniye CETINBAS, Marc I. DAMELIN, Eugene W. KELLEHER, Timothy B. LOWINGER, Joshua D. THOMAS, Dorin TOADER, Ling XU, Liping YANG
  • Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
    Patent number: 10072299
    Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: September 11, 2018
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Raghida Bukhalid, Michael Feldhaus, Anne Richard, Neeraj Kohli, Eric Krauland, Jeffrey David Kearns, Alexey A. Lugovskoy, Ulrik Nielsen
  • Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
    Patent number: 9902999
    Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: February 27, 2018
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Raghida Bukhalid, Michael Feldhaus, Anne Richard, Neeraj Kohli, Eric Krauland, Jeffrey David Kearns, Alexey A. Lugovskoy, Ulrik Nielsen
  • Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
    Patent number: 9885087
    Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: February 6, 2018
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Raghida Bukhalid, Michael Feldhaus, Anne Richard, Neeraj Kohli, Eric Krauland, Jeffrey David Kearns, Alexey A. Lugovskoy, Ulrik Nielsen
  • MONOCLONAL AND OLIGOCLONAL ANTI-EGFR ANTIBODIES FOR USE IN THE TREATMENT OF TUMORS EXPRESSING PREDOMINANTLY HIGH AFFINITY EGFR LIGANDS OR TUMORS EXPRESSING PREDOMINANTLY LOW AFFINITY EGFR LIGANDS
    Publication number: 20170356049
    Abstract: Disclosed are pharmaceutical preparations for, and methods for determining, appropriate and effective treatment with therapeutic agents comprising a single species of anti-EGFR monoclonal antibody or therapeutic agents comprising a plurality of species of such antibodies, as well as kits useful for making such determinations.
    Type: Application
    Filed: March 17, 2017
    Publication date: December 14, 2017
    Inventors: Raghida BUKHALID, Ulrik NIELSEN, Shannon WERNER, Jeffrey David KEARNS
  • ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND USES THEREOF
    Publication number: 20170314079
    Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
    Type: Application
    Filed: June 22, 2017
    Publication date: November 2, 2017
    Inventors: Raghida BUKHALID, Michael J. FELDHAUS, Anne KING, Neeraj KOHLI, Eric M. KRAULAND, Jeffrey D. KEARNS, Alexey Alexandrovich LUGOVSKOY, Ulrik B. NIELSEN
  • MONOCLONAL AND OLIGOCLONAL ANTI-EGFR ANTIBODIES FOR USE IN THE TREATMENT OF TUMORS EXPRESSING PREDOMINANTLY HIGH AFFINITY EGFR LIGANDS OR TUMORS EXPRESSING PREDOMINANTLY LOW AFFINITY EGFR LIGANDS
    Publication number: 20160083800
    Abstract: Disclosed are pharmaceutical preparations for, and methods for determining, appropriate and effective treatment with therapeutic agents comprising a single species of anti-EGFR monoclonal antibody or therapeutic agents comprising a plurality of species of such antibodies, as well as kits useful for making such determinations.
    Type: Application
    Filed: August 24, 2015
    Publication date: March 24, 2016
    Inventors: Raghida BUKHALID, Ulrik NIELSEN, Shannon WERNER, Jeffrey David KEARNS
  • ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND USES THEREOF
    Publication number: 20160002339
    Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
    Type: Application
    Filed: May 28, 2015
    Publication date: January 7, 2016
    Inventors: Raghida BUKHALID, Michael FELDHAUS, Anne KING, Neeraj KOHLI, Eric KRAULAND, Ulrik NIELSEN
  • Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
    Patent number: 9226964
    Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
    Type: Grant
    Filed: January 3, 2014
    Date of Patent: January 5, 2016
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Raghida Bukhalid, Michael Feldhaus, Anne King, Neeraj Kohli, Eric Krauland, Jeffrey David Kearns, Alexey A. Lugovskoy, Ulrik Nielsen
  • ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND USES THEREOF
    Publication number: 20150376284
    Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
    Type: Application
    Filed: September 8, 2015
    Publication date: December 31, 2015
    Applicant: Adimab, LLC
    Inventors: Raghida BUKHALID, Michael FELDHAUS, Anne KING, Neeraj KOHLI, Eric KRAULAND, Jeffrey David KEARNS, Alexey A. LUGOVSKOY, Ulrik NIELSEN
  • ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND USES THEREOF
    Publication number: 20150368361
    Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
    Type: Application
    Filed: September 8, 2015
    Publication date: December 24, 2015
    Applicant: Adimab, LLC
    Inventors: RAGHIDA BUKHALID, MICHAEL FELDHAUS, ANNE KING, NEERAJ KOHLI, ERIC KRAULAND, ULRIK NIELSEN
  • ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND USES THEREOF
    Publication number: 20150368347
    Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
    Type: Application
    Filed: September 8, 2015
    Publication date: December 24, 2015
    Applicant: ADIMAB, LLC
    Inventors: Raghida BUKHALID, Michael FELDHAUS, Anne KING, Neeraj KOHLI, Eric KRAULAND, Jeffrey David KEARNS, Alexey A. LUGOVSKOY, Ulrik NIELSEN
  • ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND USES THEREOF
    Publication number: 20150368346
    Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
    Type: Application
    Filed: September 8, 2015
    Publication date: December 24, 2015
    Applicant: ADIMAB, LLC
    Inventors: Raghida BUKHALID, Michael FELDHAUS, Anne KING, Neeraj KOHLI, Eric KRAULAND, Jeffrey David KEARNS, Alexey A. LUGOVSKOY, Ulrik NIELSEN
  • Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
    Patent number: 9044460
    Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: June 2, 2015
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Raghida Bukhalid, Michael Feldhaus, Anne King, Neeraj Kohli, Eric Krauland, Ulrik Nielsen
  • ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND USES THEREOF
    Publication number: 20140234314
    Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
    Type: Application
    Filed: April 30, 2014
    Publication date: August 21, 2014
    Applicant: MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Raghida BUKHALID, Michael FELDHAUS, Anne KING, Neeraj KOHLI, Eric KRAULAND, Jeffrey David KEARNS, Alexey A. LUGOVSKOY, Ulrik NIELSEN
  • MONOCLONAL AND OLIGOCLONAL ANTI-EGFR ANTIBODIES FOR USE IN THE TREATMENT OF TUMORS EXPRESSING PREDOMINANTLY HIGH AFFINITY EGFR LIGANDS OR TUMORS EXPRESSING PREDOMINANTLY LOW AFFINITY EGFR LIGANDS
    Publication number: 20140170668
    Abstract: Disclosed are pharmaceutical preparations for, and methods for determining, appropriate and effective treatment with therapeutic agents comprising a single species of anti-EGFR monoclonal antibody or therapeutic agents comprising a plurality of species of such antibodies, as well as kits useful for making such determinations.
    Type: Application
    Filed: February 14, 2014
    Publication date: June 19, 2014
    Applicant: Merrimack Pharmaceuticals, Inc.
    Inventors: Raghida BUKHALID, Ulrik NIELSEN, Shannon WERNER, Jeffrey David KEARNS
  • ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND USES THEREOF
    Publication number: 20140127207
    Abstract: Anti-EGFR antibodies, therapeutic compositions comprising combinations of anti-EGFR antibodies, as well as methods for using such antibodies and compositions to treat EGFR-related disorders (e.g., cancers), are disclosed.
    Type: Application
    Filed: January 3, 2014
    Publication date: May 8, 2014
    Applicant: MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Raghida BUKHALID, Michael FELDHAUS, Anne KING, Neeraj KOHLI, Eric KRAULAND, Jeffrey David KEARNS, Alexey A. LUGOVSKOY, Ulrik NIELSEN